Pacira BioSciences' Common Equity fell 298.42% to $727.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $727.2 million, marking a year-over-year decrease of 298.42%. This contributed to the annual value of $778.3 million for FY2024, which is 1054.81% down from last year.
As of Q3 2025, Pacira BioSciences' Common Equity stood at $727.2 million, which was down 298.42% from $757.8 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Common Equity registered a high of $892.2 million during Q1 2024, and its lowest value of $650.8 million during Q1 2021.
Moreover, its 5-year median value for Common Equity was $768.0 million (2023), whereas its average is $771.5 million.
Its Common Equity has fluctuated over the past 5 years, first surged by 7703.76% in 2021, then plummeted by 1381.94% in 2025.
Quarter analysis of 5 years shows Pacira BioSciences' Common Equity stood at $730.4 million in 2021, then increased by 6.11% to $775.0 million in 2022, then rose by 12.27% to $870.1 million in 2023, then dropped by 10.55% to $778.3 million in 2024, then fell by 6.57% to $727.2 million in 2025.
Its Common Equity stands at $727.2 million for Q3 2025, versus $757.8 million for Q2 2025 and $798.5 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value